Skip to Content

Octreotide Injection

Last Updated: December 26, 2018
Status: Current

Products Affected - Description
    • Sandostatin injection, Novartis, 1000 mcg/mL, 5 mL vial, 1 count, NDC 00078-0184-25
    • Sandostatin injection, Novartis, 200 mcg/mL, 5 mL vial, 1 count, NDC 00078-0183-25
    • Octreotide Acetate injection, Hikma, 1,000 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6178-10
    • Octreotide Acetate injection, Hikma, 100 mcg/mL, 1 mL vial, 10 count, NDC 00641-6175-10
    • Octreotide Acetate injection, Hikma, 200 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6177-10
    • Octreotide Acetate injection, Hikma, 500 mcg/mL, 1 mL vial, 10 count, NDC 00641-6176-10
    • Octreotide Acetate injection, Sun Pharma, 100 mcg/mL, 1 mL ampule, 10 count, NDC 62756-0349-44
    • Octreotide Acetate injection, Sun Pharma, 1000 mcg/mL, 5 mL vial, 1 count, NDC 62756-0352-40
    • Octreotide Acetate injection, Sun Pharma, 200 mcg/mL, 5 mL vial, 1 count, NDC 62756-0350-40
    • Octreotide Acetate injection, Sun Pharma, 50 mcg/mL, 1 mL ampule, 10 count, NDC 62756-0348-44
    • Octreotide Acetate injection, Sun Pharma, 500 mcg/mL, 1 mL ampule, 10 count, NDC 62756-0351-44
Reason for the Shortage
    • Fresenius Kabi has octreotide available.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional has octreotide available.
    • Sagent has octreotide available.
    • Sun Pharma did not provide a reason for the shortage.
    • Teva has octreotide available.
    • Novartis has Sandostatin available. The 200 mcg/mL 5 mL vials were discontinued in early-2018.
Available Products
    • Sandostatin injection, Novartis, 100 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0181-01
    • Sandostatin injection, Novartis, 50 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0180-01
    • Sandostatin injection, Novartis, 500 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0182-01
    • Octreotide Acetate injection, Fresenius Kabi, 100 mcg/mL, 1 mL vial, 10 count, NDC 63323-0376-01
    • Octreotide Acetate injection, Fresenius Kabi, 1000 mcg/mL, 5 mL vial, 1 count, NDC 63323-0379-05
    • Octreotide Acetate injection, Fresenius Kabi, 200 mcg/mL, 5 mL vial, 1 count, NDC 63323-0378-05
    • Octreotide Acetate injection, Fresenius Kabi, 50 mcg/mL, 1 mL vial, 10 count, NDC 63323-0365-01
    • Octreotide Acetate injection, Fresenius Kabi, 500 mcg/mL, 1 mL vial, 10 count, NDC 63323-0377-01
    • Octreotide Acetate injection, Hikma, 50 mcg/mL, 1 mL vial, 10 count, NDC 00641-6174-10
    • Octreotide Acetate injection, Mylan Institutional, 100 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0245-01
    • Octreotide Acetate injection, Mylan Institutional, 50 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0239-01
    • Octreotide Acetate injection, Mylan Institutional, 500 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0246-01
    • Octreotide Acetate injection, Sagent, 100 mcg/mL, 1 mL vial, 10 count, NDC 25021-0452-01
    • Octreotide Acetate injection, Sagent, 1000 mcg/mL, 5 mL vial, 1 count, NDC 25021-0455-05
    • Octreotide Acetate injection, Sagent, 200 mcg/mL, 5 mL vial, 1 count, NDC 25021-0454-05
    • Octreotide Acetate injection, Sagent, 50 mcg/mL, 1 mL vial, 10 count, NDC 25021-0451-01
    • Octreotide Acetate injection, Sagent, 500 mcg/mL, 1 mL vial, 10 count, NDC 25021-0453-01
    • Octreotide Acetate injection, Teva, 100 mcg/mL, 1 mL vial, 25 count, NDC 00703-3311-04
    • Octreotide Acetate injection, Teva, 1000 mcg/mL, 5 mL vial, 1 count, NDC 00703-3343-01
    • Octreotide Acetate injection, Teva, 200 mcg/mL, 5 mL vial, 1 count, NDC 00703-3333-01
    • Octreotide Acetate injection, Teva, 50 mcg/mL, 1 mL vial, 25 count, NDC 00703-3301-04
    • Octreotide Acetate injection, Teva, 500 mcg/mL, 1 mL vial, 25 count, NDC 00703-3321-04

Estimated Resupply Dates

    • Hikma has octreotide 1000 mcg/mL 5 mL vials on back order and the company estimates a release date of January 2019. The 100 mcg/mL 1 mL vials, 500 mcg/mL 1 mL vials, and 200 mcg/mL 5 mL vials are available with a short expiration date of March 2019.
    • Sun Pharma has all octreotide presentations on back order and the company cannot estimate a release date.

Updated

Updated December 26, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 16, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide